Financial Performance - The total revenue for the year ending December 31, 2025, was RMB 324,158,000, a decrease from RMB 379,600,000 in 2024, representing a decline of approximately 14.6%[3] - The gross profit for the same period was RMB 96,100,000, compared to RMB 52,600,000 in 2024, indicating an increase of approximately 82.8%[3] - The net loss for the year was RMB 26,255,000, a significant improvement from a net loss of RMB 53,357,000 in 2024, reflecting a reduction of approximately 50.8%[4] - The basic and diluted loss per share for the year was RMB 4.22, down from RMB 20.20 in 2024, representing an improvement of approximately 79.0%[4] - The group reported a net loss of approximately RMB 26.3 million for the year ended December 31, 2025, a reduction of about 50.8% from RMB 53.4 million in 2024[85] - The net loss before tax for 2025 was RMB (26,255,000), an improvement from RMB (53,480,000) in 2024[36] Assets and Liabilities - The total assets as of December 31, 2025, were RMB 331,986,000, compared to RMB 317,890,000 in 2024, showing an increase of approximately 4.3%[5] - The total liabilities decreased from RMB 725,065,000 in 2024 to RMB 621,096,000 in 2025, a reduction of approximately 14.3%[5] - As of December 31, 2025, the company's total liabilities amounted to approximately RMB 605,734,000, with net liabilities of RMB 273,833,000[13] - The total borrowings of the company were approximately RMB 316,126,000, with RMB 42,705,000, RMB 245,316,000, and RMB 28,105,000 being overdue and required to be repaid within the next twelve months[13] - The company's cash and bank balances were only approximately RMB 7,221,000 as of December 31, 2025[13] Revenue Breakdown - The group generated revenue of RMB 24,158,000 for the year ending December 31, 2025, compared to RMB 37,960,000 for the year ending December 31, 2024, reflecting a decline of approximately 36.7%[21] - The agency service revenue increased significantly to RMB 9,629,000 in 2025 from RMB 374,000 in 2024, marking a growth of over 2,500%[21] - The healthcare-related service revenue decreased to RMB 14,529,000 in 2025 from RMB 37,586,000 in 2024, representing a decline of approximately 61.3%[21] Cash Flow and Financing - The group is actively negotiating with lenders to extend the repayment dates of overdue loans and to secure new financing sources to repay these debts[18] - The group plans to secure new financing sources or strategic capital investments within the next twelve months to support its operations[22] - The group is facing significant uncertainty regarding its ability to continue as a going concern, contingent on successful negotiations with lenders and the realization of its future plans[19] - The group has cash and bank balances of only approximately RMB 7.2 million, indicating significant liquidity pressure[92] - The company is actively negotiating with major lenders to restructure debt arrangements, including extending repayment terms and seeking waivers for certain restrictive covenants[121] Strategic Plans and Developments - The company plans to continue its market expansion and product development strategies, although specific figures and timelines were not disclosed in the report[6] - The company aims to develop a comprehensive platform covering health product supply and health screening services, integrating AI for bone health and offering personalized medical care[18] - The company is transitioning from traditional pharmaceutical sales to an AI-driven health management platform covering the entire cycle of "detection - treatment - recovery"[74] - The group is focusing on developing an AI-enabled Health Management Platform, which includes three layers: professional medical, medical technology, and recovery/management interfaces[95] Governance and Compliance - The company has complied with the Corporate Governance Code, with a separation of roles between the Chairman and the CEO effective from May 19, 2025[107] - The audit committee has acknowledged the significant uncertainty regarding the effectiveness of the measures taken to ensure the group's ongoing viability[94] - The audit committee reviewed the audited annual results for the year ending December 31, 2025, and recommended their adoption by the board[113] Shareholder and Equity Changes - Following the loan capitalization completed on February 21, 2025, Golden Base's shareholding in the company increased from 15.26% to 45.08%[7] - The company issued 410,156,509 new shares to Golden Base and Mr. Yang, with 263,636,363 shares for a debt settlement of approximately HKD 71,103,000 and 146,520,146 shares for a debt of RMB 44,000,000[69] - The company's share capital as of December 31, 2025, was adjusted to 674,246,000 shares after a share consolidation and capitalized loans[67] Legal and Regulatory Matters - The company has not received any updates regarding the second-instance court proceedings related to the financial data disclosure case as of the date of the consolidated financial statements[49] - The court ruled in favor of the company, ordering Beijing Kangchen Bio to provide all financial data since its establishment in 2017, but the company has appealed this decision[49]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性 亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或因倚賴該等內容而引致 之任何損失承擔任何責任。 中国泰凌医药集团 CHINA NT PHARMA GROUP （於開曼群島註冊成立之有限公司） 除上文所披露者外，該公告所載之所有其他資料及內容維持不變。本公告屬補充性質，應與該 公告一併閱讀。 - 1 - 本公司已定於 2026 年 3 月 31 日（星期二）舉行董事會會議，以考慮及批准本集團截至 2025 年 12 月 31 日止年度之年度業績及其刊發。 （股份代號：1011） 盈利警告虧損減少 補充公告 本公告乃由中國泰凌醫藥集團有限公司（「本公司」，連同其附屬公司統稱「本集團」）根據 香港聯合交易所有限公司證券上市規則（「上市規則」）第 13.09(2)(a)條及香港法例第 571 章證券及期貨條例第 XIVA 部項下內幕消息條文（定義見上市規則）而作出。 茲提述本公司日期為 2026 年 2 月 26 日之盈利警告公告（「該公告」）。除另有指明者外， 本公告所用之詞彙與該公告所界定者具有相同涵 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 中國泰凌醫藥集團有限公司 呈交日期： 2026年3月25日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 01011 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | | 已發行股份（不 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 表 明 概 不 會 就 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 （於開曼群島註冊成立之有限公司） （股份代號：1011） 完成有關收購目標公司100%已發行股份及 根據特別授權發行代價股份之主要交易 茲 提 述 中 國 泰 凌 醫 藥 集 團 有 限 公 司（「本公司」），連 同 其 附 屬 公 司 統 稱「本集團」） 日期為2025年4月28日、2025年4月29日 及2025年12月18日 的 公 告，以 及 本 公 司 日 期 為2025年12月24日 的 通 函（「通 函」），內 容 有 關（其 中 包 括）涉 及 根 據 特 別 授 權 發 行代價股份之收購目標公司100%已 發 行 股 份 之 主 要 交 易。除 另 有 界 定 外，本 公 告 所 用 詞 彙 與 該 通 函 所 界 定 者 具 有 相 同 涵 義。 完成收購事項 董 事 會 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 （於開曼群島註冊成立之有限公司） （股份代號：1011） 董事會會議日期 中 國 泰 凌 醫 藥 集 團 有 限 公 司（「本公司」）董 事 會（「董事會」）謹 此 宣 佈，董 事 會 會 議 將 於 二 零 二 六 年 三 月 三 十 一 日（星 期 二）舉 行，藉 以（其 中 包 括）批 准 本 公 司 及 其 附 屬 公 司 截 至 二 零 二 五 年 十 二 月 三 十 一 日 止 年 度 之 全 年 業 績，以 及 考 慮 末 期 股 息 之 建 議（如 有）。 承董事會命 中國泰淩醫藥集團有限公司 主 席 吳 鐵 香 港，2026年3月18日 於 本 公 告 日 期，執 行 董 事 為 吳 鐵 先 生 及 吳 靜 美 女 士；非 執 行 董 事 為 錢 唯 博 士 及 錢 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國泰凌醫藥集團有限公司 呈交日期: 2026年3月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01011 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 62,592,500,000 | USD | | 0.0000008 | USD | | 50,074 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 62,592,500,000 | USD | | 0.0000008 | USD | | 50,074 | | 2. ...

Core Viewpoint - The company expects to report a net loss attributable to shareholders of approximately 25 million to 30 million RMB for the fiscal year ending December 31, 2025, representing a decrease of about 43.8% to 53.2% compared to the same period in 2024 [1] Summary by Relevant Categories Financial Performance - The anticipated reduction in loss is primarily due to the absence of a one-time non-cash fair value loss of approximately 29.5 million RMB related to the equity of Beijing Kangchen Biotechnology Co., Ltd. recognized in the previous year [1] - The company expects to record a fair value gain of approximately 14 million RMB on financial assets (specifically the aforementioned equity) in the current fiscal year [1]

Core Viewpoint - The company, TaiLing Pharmaceutical (01011), anticipates a significant reduction in net loss attributable to shareholders for the fiscal year ending December 31, 2025, projecting a loss between approximately RMB 25 million to RMB 30 million, which represents a decrease of about 43.8% to 53.2% compared to the previous year's loss of approximately RMB 53.4 million [1] Group 1 - The expected reduction in loss is primarily attributed to the absence of a one-time non-cash fair value loss of approximately RMB 29.5 million related to the equity of Beijing Kangchen Biotechnology Co., Ltd., which was recognized in the previous year [1] - The company also reported a fair value gain of approximately RMB 14 million on financial assets (the aforementioned equity) for the current fiscal year [1]

Group 1 - The company, TaiLing Pharmaceutical (01011.HK), expects to record a net loss attributable to shareholders of approximately RMB 25 million to RMB 30 million for the fiscal year ending December 31, 2025, which represents a significant decrease of about 43.8% to 53.2% compared to the net loss of approximately RMB 53.4 million for the fiscal year ending December 31, 2024 [1] - The anticipated reduction in loss is primarily attributed to the absence of a one-time non-cash fair value loss of approximately RMB 29.5 million related to the equity of Beijing Kangchen Biotechnology Co., Ltd., which was recognized in the previous fiscal year [1] - Additionally, the company expects to record a fair value gain of approximately RMB 14 million on financial assets, specifically the aforementioned equity, in the current fiscal year [1]

Core Viewpoint - The company expects a significant reduction in net loss attributable to shareholders for the fiscal year ending December 31, 2025, projecting a loss between approximately RMB 25 million and RMB 30 million, which represents a decrease of about 43.8% to 53.2% compared to the previous year's loss of approximately RMB 53.4 million [1] Group 1 - The anticipated reduction in loss is primarily due to the absence of a one-time non-cash fair value loss of approximately RMB 29.5 million related to the equity of Beijing Kangchen Biotechnology Co., Ltd., which was recognized in the previous year [1] - The company expects to report a fair value gain of approximately RMB 14 million on financial assets (specifically the aforementioned equity) for the current fiscal year [1]